Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]

证券日报网讯 9月3日晚间，康恩贝发布公告称，近日，公司收到国家药品监督管理局核准签发的苓桂 术甘汤颗粒《药品注册证书》。 （文章来源：证券日报） ...

北京商报讯(记者王寅浩实习记者宋雨盈)9月3日，康恩贝（600572）发布公告称，公司近日收到国家药 品监督管理局核准签发的苓桂术甘汤颗粒《药品注册证书》。公告显示，苓桂术甘汤颗粒具有温阳化 饮、健脾利湿功效，主治中阳不足之痰饮。 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

证券简称：康恩贝 证券代码：600572 编号：2025-045 浙江康恩贝制药股份有限公司 近日，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）收到国家药品 监督管理局（以下简称"国家药监局"）核准签发的苓桂术甘汤颗粒《药品注册证书》， 现将相关情况公告如下： 一、药品注册证书的主要内容 药品名称：苓桂术甘汤颗粒 剂型：颗粒剂 规格：每袋装 10g（相当于饮片 55.2g） 注册分类：中药 3.1 类 上市许可持有人：浙江康恩贝制药股份有限公司 批准文号：国药准字 C20250010 证书编号：2025S02565 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 公司于 2024 年 6 月向国家药监局药品审评中心递交了苓桂术甘汤颗粒的药品注册申 请并获受理，于近日获得国家药监局核准签发的《药品注册证书》。 截至目前，本公司针对该药品已投入研发费用约 1,270 万元（人民币，下同）。 三、其他相关情况 根据国家药监局网站显示，截至本公告日，苓桂术甘（汤）颗粒共有 4 个药品批准文 号，本公司为第 4 家获批。 米 ...

人民财讯9月3日电，康恩贝（600572）9月3日晚间公告，公司近日收到国家药监局核准签发的苓桂术甘 汤颗粒《药品注册证书》。苓桂术甘汤颗粒来源于汉代张仲景《金匮要略》，具有温阳化饮、健脾利湿 功效，主治中阳不足之痰饮。 ...

苓桂术甘汤颗粒来源于汉代张仲景《金匮要略》，具有温阳化饮、健脾利湿功效，主治中阳不足之痰 饮。症见胸胁支满，目眩心悸，短气而咳，舌苔白滑，脉弦滑。处方由茯苓、桂枝、白术、甘草组成。 智通财经APP讯，康恩贝(600572.SH)发布公告，近日，公司收到国家药品监督管理局(简称"国家药监 局")核准签发的苓桂术甘汤颗粒《药品注册证书》。 ...